Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Immunome, Inc. < Previous 1 2 Next > Immunome Appoints Phil Tsai as Chief Technical Officer June 27, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Completion of Purchase of Assets from Atreca May 20, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Promotion of Max Rosett to Chief Financial Officer May 17, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports First Quarter 2024 Financial Results and Provides Business Update May 14, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at 2024 Bank of America Healthcare Conference May 08, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Appoints Kinney Horn as Chief Business Officer May 02, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting April 05, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets March 28, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala March 26, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Participate in the Leerink Partners Global Biopharma Conference March 07, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference March 01, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors February 20, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares February 16, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Pricing of Public Offering of Common Stock February 13, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Announces Proposed Public Offering of Common Stock February 13, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals February 06, 2024 From Immunome, Inc. Via Business Wire Tickers ADXS IMNM Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 05, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform January 08, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM ZNTL Immunome Appoints Phil Roberts as Chief Technical Officer January 04, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Appoints Carol A. Schafer to Board of Directors January 02, 2024 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Acquire Antibody-Related Assets and Materials from Atreca December 26, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome to Present at the Stifel 2023 Healthcare Conference November 10, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports Third Quarter 2023 Financial Results November 09, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Appoints Jean-Jacques Bienaimé to Board of Directors November 08, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer October 19, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies October 03, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports Second Quarter 2023 Financial Results August 09, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity May 23, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM Immunome Reports First Quarter 2023 Financial Results May 05, 2023 From Immunome, Inc. Via Business Wire Tickers IMNM < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.